Kerato’s innovative “biosynthetic cornea” provides a promising alternative to traditional donor corneal transplants. Designed for one-time use, this injectable device is administered single-handedly. It forms a self-sealing gel in the eye, which reduces inflammation, promotes tissue remodelling, and supports re-epithelialisation, achieving similar clinical results to those seen with syngeneic grafts.
The development of Kerato’s corneal regenerative therapies is backed by years of research and collaboration with medical professionals. These partnerships have enabled a deep understanding of how the technology can be used to address significant health issues. The product has broad clinical and veterinary applications, offering solutions for conditions such as perforations, ulcers, thinned corneas, and advanced corneal diseases. Early intervention, integration into clinical pathways, faster recovery times, and improved patient quality of life are all benefits associated with this innovative therapy.
The veterinary market has an increasing demand for corneal treatments, especially given the rising pet population and growing awareness of pet health. Pet owners are more willing to invest in veterinary eye care, including procedures to address corneal ulcers, a common issue in horses and dogs. Kerato’s device is designed to provide veterinarians with a straightforward, effective alternative to donor transplants, enabling them to treat corneal injuries and improve animal eyesight.
With an ageing global population, there is a rising need for corneal solutions. Vision impairment affects millions, with the cornea being the most transplanted human tissue worldwide. Yet, access to donor material remains limited, with 55% of the world’s population lacking access to necessary tissue. In many developing regions, economic and cultural factors contribute to a shortage of donor corneas.
Che Connon, co-founder of Kerato, emphasised the urgent need for bioengineered solutions to meet the global demand for corneal transplants. Millions are awaiting cornea replacements to regain their sight and quality of life. Through their efforts, Kerato aims to bridge these gaps by advancing medical devices that make bioengineered corneas a viable solution for overcoming health challenges and reducing disparities in medical access.
Kerato’s biosynthetic cornea not only offers a groundbreaking approach to corneal transplants but also has the potential to address a critical gap in global health, providing a more accessible, effective solution for both human and veterinary eye care.
BSF Enterprise plc (LON:BSFA), the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is unlocking the next generation of biotech solutions. It is achieving this through an acquisition-led growth strategy to drive the development of lab-grown tissues.
